文献速递糖尿病

1型糖尿病患者接种前血糖目标范围内时间与SARS-CoV-2疫苗抗体应答相关

Prevaccination Glucose Time in Range Correlates With Antibody Response to SARS-CoV-2 Vaccine in Type 1 Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

该前瞻性研究纳入26例1型糖尿病患者,接种两剂BNT162b2疫苗(间隔21天),随访6个月。接种前2周CGM指标(TIR、TAR)与疫苗后IgG应答相关,达到接种前血糖目标(TIR≥70%、TAR≤25%)者中和抗体滴度更强,且独立于HbA1c。

要点

  • 接种前2周TIR与疫苗后IgG正相关(r=0.75,P=.02),TAR与IgG负相关(r=-0.81,P=.008)。
  • 达到接种前TIR≥70%和TAR≤25%目标者中和抗体滴度更强(分别P<.0001和P=.008),与HbA1c无关。
  • 研究期间TIR与随访期IgG正相关(r=0.93,P<.0001),TAR与IgG负相关(r=-0.84,P<.0001)。

核心结论

  • 在1型糖尿病患者中,接种前2周的血糖谱与更强的刺突抗体结合和中和作用相关,提示控制良好的血糖在疫苗接种效力中可能发挥作用。

研究设计与样本

  • 前瞻性研究,纳入26例计划接种2剂BNT162b2(间隔21天)的1型糖尿病患者,随访6个月,定期评估SARS-CoV-2抗体和血糖控制。

主要发现

  • 接种前HbA1c与疫苗后刺突IgG无关(r=-0.33;P=.14)。
  • 接种前2周CGM指标与疫苗后IgG应答相关:TIR r=0.75,P=.02;TAR r=-0.81,P=.008。
  • 达到接种前TIR≥70%和TAR≤25%推荐目标者中和抗体滴度更强(分别P<.0001和P=.008),与HbA1c无关。
  • 研究期间TIR与随访期IgG相关(r=0.93;P<.0001),TAR与IgG相关(r=-0.84;P<.0001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Poor glucose control has been associated with increased mortality in COVID-19 patients with type 1 diabetes (T1D). OBJECTIVE: This work aimed to assess the effect of prevaccination glucose control on antibody response to the SARS-CoV-2 vaccine BNT162b2 in T1D. METHODS: We studied 26 patients with T1D scheduled to receive 2 doses, 21 days apart, of BNT162b2, followed prospectively for 6 months with regular evaluation of SARS-CoV-2 antibodies and glucose control. Immunoglobulin G (IgG) to spike glycoprotein were assessed by enzyme-linked immunosorbent assay, and serum neutralization by a live SARS-CoV-2 assay (Vero E6 cells system). Glycated hemoglobin A1c (HbA1c) and continuous glucose monitoring (CGM), including time in range (TIR) and above range (TAR), were collected. The primary exposure and outcome measures were prevaccination glucose control, and antibody response after vaccination, respectively. RESULTS: Prevaccination HbA1c was unrelated to postvaccine spike IgG (r = -0.33; P = .14). Of note, the CGM profile collected during the 2 weeks preceding BNT162b2 administration correlated with postvaccine IgG response (TIR: r = 0.75; P = .02; TAR: r = -0.81; P = .008). Patients meeting the recommended prevaccination glucose targets of TIR (≥ 70%) and TAR (≤ 25%) developed stronger neutralizing antibody titers (P < .0001 and P = .008, respectively), regardless of HbA1c. Glucose control along the study time frame was also associated with IgG response during follow-up (TIR: r = 0.93; P < .0001; TAR: r = -0.84; P < .0001). CONCLUSION: In T1D, glucose profile during the 2 weeks preceding vaccination is associated with stronger spike antibody binding and neutralization, highlighting a role for well-controlled blood glucose in vaccination efficacy.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Alhamar G, Briganti S, Maggi D, et al. Prevaccination Glucose Time in Range Correlates With Antibody Response to SARS-CoV-2 Vaccine in Type 1 Diabetes. J Clin Endocrinol Metab. 2023. PMID: 36611249. doi:10.1210/clinem/dgad001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。